Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Current Oncology Reports|March 15, 2023
AXL Inhibitors: Status of Clinical DevelopmentSheena Bhalla, David E GerberClinical Lymphoma, Myeloma & Leukemia|July 14, 2016
Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future DirectionsSheena Bhalla, Douglas Tremblay, John MascarenhasClinical Chemistry|January 4, 2024
Emerging Strategies in Lung Cancer Screening: Blood and BeyondSheena Bhalla, Sofia Yi, David E GerberCancer Journal (Sudbury, Mass.)|December 10, 2020
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future DirectionsSheena Bhalla, Deborah Blythe Doroshow, Fred R HirschOncology (Williston Park, N.Y.)|May 31, 2018
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid MalignanciesKelsey Sokol, Douglas Tremblay, Sheena Bhalla, et al.Oncology (Williston Park, N.Y.)|April 24, 2018
Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid LeukemiaDouglas Tremblay, Kelsey Sokol, Sheena Bhalla, et al.The British Journal of Ophthalmology|April 23, 2013
Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acidSheena Bhalla, Deval Joshi, Shaminder Bhullar, et al.Carcinogenesis|February 5, 2019
Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemiaGeetanjali R Kamath, Douglas Tremblay, Alexander Coltoff, et al.The Oncologist|January 11, 2024
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung CancerDavid E Gerber, Yating Wang, Suresh S Ramalingam, et al.Clinical Lung Cancer|June 6, 2025
Mortality in a Diverse, Real-World Lung Cancer Screening CohortMary E Gwin, Tanushree Prasad, Urooj Wahid, et al.Pageof 3